Novavax (NVAX) investor relations material

Growth strategy and partnerships

• New growth strategy launched in January 2025, focusing on immediate monetization through partnerships and licensing, with a $30 million upfront payment from Pfizer and potential for $70 million in milestones per field, plus royalties for decades.

• Four new Material Transfer Agreements (MTAs) signed in early 2025, including with a top 10 global pharma and oncology leader, expanding Matrix-M's reach into infectious disease and oncology.

• Over 50% of the projected global vaccine market opportunity in oncology and infectious disease is under assessment or potential assessment via partners, covering 30 unique disease fields.

• Non-exclusive licensing approach enables multiple partners in overlapping fields, increasing probability of success and revenue streams from upfronts, milestones, and royalties.

• Matrix-M's immunologic properties, including Th1-profiled adjuvant effects and induction of cell-mediated immunity, are being leveraged in both infectious disease and oncology collaborations.

Key licensing agreements and market opportunities

• Pfizer agreement includes $30 million upfront, up to $250 million in milestones, and potential for over $1 billion in royalties over 20 years if successful.

• Recent MTA with another major pharma covers nine fields, each with potential for over $1 billion if successful.

• Sanofi partnership (2024) covers commercialization of Nuvaxovid, development of a combination influenza/COVID vaccine, and Matrix-M in preclinical work, with $425 million in milestones remaining.

• Sanofi holds nearly half of the $6 billion flu market, and the combination COVID-flu market is expected to reach $12 billion, with Sanofi positioned as a key player.

• Sanofi's CIC programs, combining Nuvaxovid with flu vaccines, are advancing toward pivotal trials, with strong safety and efficacy data and significant future growth potential.

R&D investments and internal pipeline

• Internal R&D focuses on leveraging external data from partners and developing new Matrix-M formulations and antigen combinations, with anticipated data readouts in the next 6–12 months.

• C. diff vaccine candidate targets a $1.5–$3 billion market, differentiated by targeting both toxin and non-toxin antigens and aiming for mucosal immunity; IND-enabling studies are underway with clinical entry targeted for 2027.

• Selective advancement of internal candidates is based on unmet medical need and market size, with C. diff as a key focus.